Loading clinical trials...

Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study) | Clinical Trials | Clareo Health

COMPLETED

Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)

NCT00615563•Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

The primary objective of this trial was to assess the presence of susceptibility to tipranavir and other ARVs of the HIV-1 isolates in treatment experienced patients. The secondary objective was to examine clinicians' use of HIV drug resistance testing in treatment experienced patients currently failing a PI based HAART regimen.

Eligibility

Age

18 - 18 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Signed patient informed consent prior to study participation.
•2. HIV-1 infected male or female ?18 years of age.
•3. Have confirmed (2 consecutive) HIV RNA ?1000 copies/mL (one of the results must be within 3 months of enrollment into the study).
•4. Current HAART regimen contains a protease inhibitor for ?3 months.
•5. Physicians considering a change in the patient?s HAART regimen. f.) History of treatment with 2 or more protease inhibitors (including the current PI). Low dose ritonavir (i.e.\< 400 mg. bid) is not counted as one of the PIs.

Exclusion Criteria

•A patient with any of the following criteria will be excluded from participation in the study:
•1. ARV medication naive.
•2. Active opportunistic infection. c.) Known or suspected non-adherence to current HAART regimen as assessed by the investigator.

Locations (36)

Boehringer Ingelheim Investigational Site

Bakersfield, California, United States

Boehringer Ingelheim Investigational Site

Beverly Hills, California, United States

Boehringer Ingelheim Investigational Site

Fountain Valley, California, United States

Boehringer Ingelheim Investigational Site

Los Angeles, California, United States

Boehringer Ingelheim Investigational Site

Los Angeles, California, United States

Boehringer Ingelheim Investigational Site

Newport Beach, California, United States

Boehringer Ingelheim Investigational Site

Oakland, California, United States

Boehringer Ingelheim Investigational Site

Stanford, California, United States

Boehringer Ingelheim Investigational Site

Daytona Beach, Florida, United States

Boehringer Ingelheim Investigational Site

Fort Lauderdale, Florida, United States

Key Dates

Start Date

March 1, 2007

Primary Completion Date

January 1, 2008

Completion Date

January 1, 2008

Last Updated

November 21, 2013

Enrollment

246

ACTUAL participants

Conditions

HIV Infections

Interventions

NO BI Drug administered

BEHAVIORAL

Sponsors

Lead Sponsor

Boehringer Ingelheim

Related Studies

Skeletal Muscle Energetics and Fatiguability in Older Individuals

NCT04142047

HIVHIV Infections

RECRUITINGPHASE3

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 21, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions